Pegcetacoplan治疗C3肾小球病和原发性免疫复合物膜增生性肾小球肾炎的真实世界结局
本研究为真实世界观察性队列研究,纳入25例对常规免疫抑制抵抗的儿童和成人C3G或原发性IC-MPGN患者,接受pegcetacoplan治疗。结果显示6个月内uPCR下降81%,68%患者uPCR<1 g/g,血清C3恢复正常或超正常,eGFR在3和6个月显著升高,12个月稳定,无严重不良事件。
要点
- Pegcetacoplan可快速持续降低C3G和原发性IC-MPGN患者蛋白尿。
- 治疗6个月uPCR下降81%,68%患者uPCR<1 g/g。
- 血清C3多数恢复正常,eGFR在3和6个月显著改善。
核心结论
- Pegcetacoplan在C3G和原发性IC-MPGN中显示快速持续疗效且安全性良好。
研究设计与样本
- 真实世界观察性队列研究,纳入25例(18例C3GN、3例DDD、4例原发性IC-MPGN)对常规免疫抑制抵抗的儿童和成人患者。
主要发现
- 基线中位uPCR为3.5 g/g,平均eGFR为74 ml/min per 1.73 m2,19/25例血清C3低。
- 治疗6个月uPCR下降81%,68%患者uPCR<1 g/g,12%完全缓解,64%部分缓解。
- 血清C3除1例疑似不依从外均升至正常或超正常范围。
- eGFR在3个月显著增加9.4 ml/min per 1.73 m2,6个月增加12 ml/min per 1.73 m2,12个月稳定。
- 4例系列活检显示C3沉积和慢性病变从完全消失到持续存在不等,偶见肾小管上皮损伤。
临床怎么用
- 对于常规免疫抑制抵抗的C3G和原发性IC-MPGN患者,pegcetacoplan可考虑作为治疗选择。
局限性
- 样本量小(25例),随访数据有限,部分患者12个月数据缺失。
- 真实世界观察性设计,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pegcetacoplan is a novel C3/C3b inhibitor with potential as a treatment for C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), both caused by complement system dysfunction. METHODS: We conducted a real-world observational cohort study to evaluate the efficacy and safety of pegcetacoplan in pediatric and adult patients, largely resistant to conventional immunosuppression. These patients were treated outside clinical trials and identified through the CompCure registry and an international survey. Changes in urine protein-to-creatinine ratio (uPCR), estimated glomerular filtration rate (eGFR), and serum C3 at one, three, six and twelve months were evaluated. RESULTS: 25 patients (18 C3 glomerulonephritis, 3 Dense Deposit Disease, 4 primary IC-MPGN) initiated pegcetacoplan therapy at a median age of 14.9 years at a median 2.7 years after diagnosis. Median uPCR at baseline was 3.5 g/g, mean eGFR was 74 ml/min per 1.73 m2, and 19 of 25 patients had low serum C3. After pegcetacoplan initiation we observed a rapid and sustained reduction of proteinuria: uPCR decreased by 81% in six months, with 68% of patients achieving under 1 g/g and 12% achieving complete and 64% partial remission. Serum C3 increased to the normal or supranormal range in all but one case with suspected non-adherence. The eGFR significantly increased by month three (9.4 ml/min per 1.73 m2) and six (12 ml/min per 1.73m2) and remained stable at twelve months in patients with available follow-up data. Sequential biopsies available in four cases showed variable changes, ranging from complete disappearance to persistence of C3 deposits, of chronic lesions, and occasional tubulo-epithelial damage. No serious adverse events occurred during 222 months of cumulative exposure. CONCLUSIONS: Pegcetacoplan demonstrated rapid and sustained efficacy with good safety despite two potential drug-related concerns in C3G and primary IC-MPGN, highlighting its potential for broader application and the need for further research to optimize patient selection and treatment strategies.
引用
- Bassanese G, Weingarten AM, Mancuso MC, et al. Real-world outcomes of pegcetacoplan treatment in C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Kidney Int. 2026. PMID: 42297103. doi:10.1016/j.kint.2026.04.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。